Clinical and Surgical Management for Placement of Osseointegrated Implants in a Patient taking Bisphosphonate Medication: Case Report / Manejo Clínico e Cirúrgico para Colocação de Implantes Osseointegrados em Paciente Em Uso de Bifosfonatos: Relato de Caso

Authors

  • Edson Junio Affonso Carvalho Brazilian Journals Publicações de Periódicos, São José dos Pinhais, Paraná
  • Yago Martins Macedo
  • Karellen Torquato Segalla
  • Caroline Águeda Corrêa
  • Fabiano Luiz Heggendorn

DOI:

https://doi.org/10.34117/bjdv7n12-343

Keywords:

Bisphosphonates, Dental Implants, Osteonecrosis, Oral surgery.

Abstract

It is important to have knowledge about bisphosphonates, their composition, presentation, mechanism of action, dosage, benefits and adverse effects, in orderto understand the behavior of these drugs in the human body and their implication in implant dentistry. At present, the risk of medication-related osteonecrosis of the jaw (MRONJ) is being widely discussed. The aim of this study was to describe a conservative protocol, in the form of a case report, for the serial placement of osseointegrated implants in a patient with a history of continuous use of 150 mg, sodium ibandronate (Osteoban®). Case Report. To report the different clinical and surgical managements required in order to avoid or minimize the risk of patients developing MRONJ after the placement of osseointegrated implants. Materials and methods. The procedures performed began with the placement of a single osseointegrated implant, assessment of the patient's postoperative condition, and then, after a control period, concluding the treatment with a more complex surgical intervention consisting of serial placement of 6 osseointegrated implants. Results. After the period of one year, the patient’s condition was found to be normal in relation to the osseointegrated implants, and there was absence of signs of development of MRONJ. Conclusions. The preoperative conduct of instituting the drug holiday of 150 mg sodium ibandronate (Osteoban®), associated with control of the serum CTx level for an extended period allowed the installation of osseointegrated implants in a patient with long-term oral administration of bisphosphonates without the development of MRONJ occurring. The surgical steps, evolving from less complex through to the last procedures, with the installation of multiple osseointegrated implants, helped to assess the risk of the patient for developing MRONJ.

References

Santos LCS, Pereira RP, Gusmão JMR, Almeida ODS. Influência do uso de bisfosfonatos em pacientessubmetidos a implantesdentários. Rev Bahiana de Odontologia 2016;7(1):22-30.

Neto AM, Gerzson AS, Fetter EP, Cortez ALV, Giudi R. Bifosfonatos em Implantodontia. Pro-Odonto Implante 2011;5(4):59-94.

Brozoski MA, Traina AA, Deboni MCZ, Marques MM, Naclério-Homem, MDG. Osteonecrose maxilar associada ao uso de bisfosfonatos. Revista Brasileira de reumatologia 2012;52(2):260-270.

Marx RE, Sawatari Y, Fortin M, Broumand V . Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors: recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75

Filleul O, Crompot E, Sassez S. Bisphosphonate inducedosteonecrosis of the jaw: a review of 2400 patient cases. J. Cancer Res. Clin. Oncol. 2010;136 (8):1117-24.

Júnior AACP, Macedo LM, Moreira LIR, Alves JFCS, Lacerda JCT. Osteonecrose dos maxilaresassociadaaouso de bisfosfonatos. Rev. Cir. Traumatol. Buco-Maxilo-Fac 2017;17(1):40-45

Souza TB. Osteonecrose dos maxilares induzida por bisfosfonatos intravenosos. Revista Cathedral 2020; 2(1):1-11.

Tripodakis AP, Kamperos G, Nikitakis N, Sklavounou-Andrikopoulou A. Implant therapy on patients treated with oral bisphosphonates. J Osseointegr 2012; 4(1):9-14.

Romero-Ruiz MM, Romero-Serrano M, Serrano-González A, Serrera-Figallo MA, Gutiérrez-Pérez JL, Torres-Lagares D. Proposal for a preventive protocol for medication-related osteonecrosis of the jaw. Med Oral Patol Oral Cir Bucal 2020;26(3):314-326.

Pichardo SEC, van der Hee JG, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ). Br J Oral Maxillofac Surg 2020; 58(7):771-776.

Torres J, Tamimi F, Garcia I, Herrero A, Rivera B, Sobrino JA, Hernández G. Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107(3):387-392.

Leite GB, Sergio Motta, Louro R, Vivacqua CFPP, Motta SHG. Osteonecrose induzida pelo uso de bisfosfonatos após instalação de implantes dentários:relato de dois casos. ImplantNews 2015; 12(6):771-778.

Troeltzsch M, Cagna D, Stähler P, Probst F, Kaeppler G, Troeltzsch M, Ehrenfeld M, Otto S. Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? J Cranio maxilla fac Surg 2016, 44(12):1945-1951.

Sousa AS, Almeida VP, Traira J, Savedra LF, RodrigueS IV, Giro G. Protocolo de atendimento odontológico de pacientes em tratamento com bisfosfonatos. Rev Saúde 2018;12(1-2): 54-61.

Mattis F, Gomes F, Mayer L. PerdaTardia de implante dentário devido a osteonecrose associada ao uso de bisfosfonatos: relato de caso clínico. Rev ACBO 2016;5(1):1-8.

Dos Santos Ferreira L, Abreu LG, Calderipe CB, Martins MD, Schuch LF, Vasconcelos ACU. Is teriparatide therapy effective for medication-related osteonecrosis of the jaw? A systematic review and meta-analysis. Osteoporos Int 2021;31.

Published

2021-12-29

How to Cite

Carvalho, E. J. A., Macedo, Y. M., Segalla, K. T., Corrêa, C. Águeda, & Heggendorn, F. L. (2021). Clinical and Surgical Management for Placement of Osseointegrated Implants in a Patient taking Bisphosphonate Medication: Case Report / Manejo Clínico e Cirúrgico para Colocação de Implantes Osseointegrados em Paciente Em Uso de Bifosfonatos: Relato de Caso. Brazilian Journal of Development, 7(12), 115304–115317. https://doi.org/10.34117/bjdv7n12-343

Issue

Section

Original Papers